Stephen V Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on shared a post on X:
”Details on safety of consolidation osimertinib after chemoradiation for EGFR mutant NSCLC from the phase III LAURA trial.
Radiation pneumonitis seen in 48% with osi and 38% with placebo, mostly low grade, 87% continued osi, 93% without recurrence.”
Title: Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study
Authors: Terufumi Kato, Xiaorong Dong, Toshiaki Takahashi, Nopadol Soparattanapaisarn, Sarayut Lucien Geater, Chih-Liang Wang, Edurne Arriola, Fedor Moiseenko, Lucy Thompson, Ellie Grainger, Elena Armenteros-Monterroso, Azura Evans, Ana Bolanos, Suresh S. Ramalingam, Shun Lu
Other Articles Featuring Stephen V Liu On OncoDaily.